Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence

Antonio Passaro1, Albrecht Stenzinger2, Solange Peters3

  • 1Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.

Cancer Cell
|November 10, 2020
PubMed

Related Concept Videos